Accelerated public health and biomedical research on priority public health objectives through collaboration between US NIH and WHO

Information

  • Research Project
  • 10051444
  • ApplicationId
    10051444
  • Core Project Number
    U01AI139547
  • Full Project Number
    3U01AI139547-02S1
  • Serial Number
    139547
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    8/23/2018 - 6 years ago
  • Project End Date
    5/31/2023 - a year ago
  • Program Officer Name
    COOMES, STEPHANIE
  • Budget Start Date
    2/3/2020 - 4 years ago
  • Budget End Date
    5/31/2020 - 4 years ago
  • Fiscal Year
    2020
  • Support Year
    02
  • Suffix
    S1
  • Award Notice Date
    2/3/2020 - 4 years ago

Accelerated public health and biomedical research on priority public health objectives through collaboration between US NIH and WHO

Abstract The World Health Organization (WHO) is the global lead agency in health matters. It fulfils a dual mandate of developing global norms and standards in health, and in providing technical assistance to member countries. More recently, WHO?s action in health emergencies has been highlighted as an important additional priority. Health research is an important component across all areas of work, and its role in research has recently been re-affirmed by the World Health Assembly. To achieve its objectives related to research, WHO maintains effective collaboration with governmental and other research organizations throughout the world, as evidenced by the network of WHO Collaborating Centres. WHO addresses a research portfolio with broad complementarity to the goals of NIH specialized institutes, covering communicable and non- communicable diseases, endemic, epidemic as well as emerging health threats. NIH as global leader in biomedical research, it is a key partner for WHO in advancing the knowledge base and in the development of new medicinal interventions. This proposal aims at enhancing collaboration between the two agencies to increase relevance, efficiency and reach of the research in support of the most pressing public health needs. This will be achieved by combining unique innovative approaches of both Organizations, building on NIH?s excellence in medical and biomedical research and its access to a vast research infrastructure, and on WHO?s global reach, its normative role and excellence in relation to implementation sciences. The collaboration will make use of WHO?s broad research programme experience, its capacity to convene and set agendas, and to develop consensus through transparent and inclusive consultative processes, with consideration of all relevant regions and communities, and taking stock of WHO?s decentralized structure. Prior work has demonstrated the power of this approach. Specific aims are dual, and cover collaborative action in the area of emerging issues in public health that require investments in basic, translational and implementation research; and a specific aims to promote work on arboviral diseases from basic to translational and implementation related research. There is significant room for expansion of collaborative activities in support of both institutions shared goals and objectives.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U01
  • Administering IC
    AI
  • Application Type
    3
  • Direct Cost Amount
    176990
  • Indirect Cost Amount
    23009
  • Total Cost
    199999
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:199999\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WORLD HEALTH ORGANIZATION
  • Organization Department
  • Organization DUNS
    480997543
  • Organization City
    GENEVA
  • Organization State
  • Organization Country
    SWITZERLAND
  • Organization Zip Code
    1211
  • Organization District
    SWITZERLAND